Randomized Controlled Trial
Copyright ©The Author(s) 2025.
World J Gastroenterol. May 14, 2025; 31(18): 105495
Published online May 14, 2025. doi: 10.3748/wjg.v31.i18.105495
Table 1 Demographic characteristics, n (%)
Characteristic
EA group (n = 30)
ET group (n = 30)
P value
Age (years), mean ± SD64.25 ± 10.4563.22 ± 5.850.794
Women24 (88.89)25 (89.29)0.763
BMI (kg/m2), mean ± SD23.94 ± 3.6924.41 ± 2.020.733
Table 2 Outcomes at different time points
Outcome
EA group (n = 30)
ET group (n = 30)
P value
VAS
    Baseline7.03 ± 0.666.95 ± 0.440.561
    T12.98 ± 0.392.07 ± 0.36< 0.001
    T23.44 ± 0.552.89 ± 0.75< 0.001
WOMAC total scores
    Baseline82.47 ± 6.4081.00 ± 4.680.262
    T148.07 ± 8.2238.4 ± 6.43< 0.001
WOMAC pain
    Baseline17.16 ± 2.1616.8 ± 2.370.507
    T110.10 ± 2.099.01 ± 3.020.191
WOMAC stiffness
    Baseline6.50 ± 1.026.03 ± 0.910.132
    T14.13 ± 1.062.77 ± 0.800.015
WOMAC function
    Baseline58.80 ± 4.0058.03 ± 3.270.555
    T133.80 ± 6.5827.50 ± 4.85< 0.001
Table 3 Effective rate between groups after treatment
Groups
Cured
Markedly effective
Effective
Ineffective
Effective rate
EA group (n = 30)0325293.33%
ET group (n = 30)0236196.67%